Mo:re is building the new gold standard for organoid-based drug development
mo:re GmbH has raised $2.5M in total funding. The most recent round was Seed. The last funding was announced in March 2025.
mo:re GmbH's investors include HTGF (High-Tech Gruenderfonds), IFB Innovationsstarter, Gilson, Nidobirds Ventures, NEDGEX.
mo:re GmbH is headquartered in Hamburg, Germany.
Mo:re is building the new gold standard for organoid-based drug development
mo:re GmbH is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"mo:re GmbH — Funding & Investors." VCBacked, March 26, 2025, https://www.vcbacked.co/company/more-gmbh. Accessed August 15, 2026.
VCBacked. (2025). mo:re GmbH — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/more-gmbh
{{cite web |title=mo:re GmbH — Funding & Investors |url=https://www.vcbacked.co/company/more-gmbh |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated